Migraine attacks were frequently diagnosed in the emergency departments. Also intravenous metoclopramide was a commonly used drug in the acute abortive treatment of migraine. However, the role of metoclopramide was based on three randomized, placebo-controlled studies, which were carried out with relatively few patients. Those trials suggested that metoclopramide produced larger improvements in visual analog scale (VAS) scores, however they revealed conflicting results and had significant methodological problems (risk of bias, allocation of concealment, intention-to-treat analysis). The investigators aimed to analyse the effects of intravenous metoclopramide in acute migraine attacks comparing with placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
148
Intravenous form of metoclopramide is in the same appearance with placebo
Intravenous form of metoclopramide is in the same appearance with placebo
Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute
Kocaeli University, Faculty of Medicine
Köseköy, Kocaeli, Turkey (Türkiye)
The difference between pain scores for both drugs
The difference between pain scores (10- point numeric rating scale score) for metoclopramide and placebo groups
Time frame: 15th and 30th minutes
Nausea and vomiting
Change in nausea/vomiting status of the participants
Time frame: 30th minute
Adverse reactions
Number of participants with adverse events
Time frame: 30th minute
Need for rescue analgesic
Number of patients needed rescue analgesic at 30th minute
Time frame: 30th minute
Change in the headache intensity
Change in the headache intensity
Time frame: Between 24th and 72th hours
Duplicative presentation to the emergency department
With telephone call
Time frame: Between 24th and 72th hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.